Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Bavarian Nordic

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MVA-BN

            Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            The three lots of MVA-BN induced similar antibody responses, meeting the study's primary endpoint, while the favourable safety profile was also confirmed without severe adverse reactions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CLP based Covid-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Recipient: AdaptVac

            Deal Size: Undisclosed Upfront Cash: $4.6 million

            Deal Type: Collaboration July 22, 2020

            Details:

            Bavarian Nordic has been granted license of AdaptVac’s proprietary capsid virus like particle (cVLP) technology for coronaviruses, including the COVID-19 indication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MVA-BN Filo vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: $13.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 18, 2020

            Details:

            Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MVA-BN-WEV

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 08, 2020

            Details:

            Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups.